Tissue repair, inflammation control, and cellular resilience are complex biological processes that depend on precise coordination between multiple molecular pathways. Peptide research has advanced toward combining compounds that engage these systems simultaneously — a concept reflected in KLOW, a multi-component peptide blend designed for experimental studies on regeneration, recovery, and inflammation modulation.
Each peptide within the blend contributes a distinct but complementary function. Together, they create a model for studying multi-pathway biological synergy, allowing researchers to explore how regenerative, immune, and vascular processes interact to restore tissue equilibrium.
KLOW is a research-grade peptide blend composed of four synergistic peptides: GHK-Cu, KPV, TB-500, and BPC-157.
Each component contributes to a unique facet of recovery and repair:
By combining these peptides, KLOW engages multiple biological pathways — promoting cellular renewal, vascular support, and immune modulation — making it an innovative tool for multi-system peptide research.
GHK-Cu (glycyl-L-histidyl-L-lysine) is a naturally occurring copper-binding tripeptide involved in cellular renewal, tissue remodeling, and antioxidant defense. It stimulates collagen and elastin synthesis, promotes angiogenesis, and increases the activity of antioxidant enzymes such as superoxide dismutase (Pickart et al.; Pickart et al.).
By influencing gene expression related to cellular growth and repair, GHK-Cu supports the regeneration of skin, connective tissue, and blood vessels. It also assists in wound remodeling and neutralization of oxidative stress, key processes in recovery and aging-related research (Pickart et al.).
Learn more in our overview:
GHK-Cu Peptide: Mechanism, Research Applications, and Therapeutic Potential
KPV (Lys‑Pro‑Val) is a tripeptide fragment of the α‑MSH (alpha‑melanocyte‑stimulating hormone) known for its anti‑inflammatory and immunomodulatory actions. In human intestinal and epithelial cell lines, KPV has been shown to inhibit NF‑κB activation and suppress pro‑inflammatory cytokines such as IL‑8, while being transported into cells via the peptide transporter PepT1 (Dalmasso et al.).
KPV enters epithelial and immune cells via PepT1 and acts to down‑regulate inflammatory signalling and promote barrier integrity. Its role in immune balance has been modelled in research exploring gut integrity and epithelial health (Land et al.)
TB‑500 is a synthetic fragment of Thymosin β4, a peptide involved in cellular migration, angiogenesis and cytoskeletal organisation. It supports tissue regeneration by enhancing actin polymerisation and up‑regulating factors such as VEGF—both essential for vascular and muscular repair in cell‑based models (Makowiecka et al.)
By stimulating cell movement and blood vessel formation, TB-500 accelerates structural recovery and promotes wound closure. It has been widely explored in muscle recovery, cardiovascular regeneration, and connective tissue repair studies (Lee et al.).
BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from gastric proteins with notable angiogenic and cytoprotective activity. It regulates fibroblast recruitment, enhances blood vessel formation, and modulates inflammatory cytokines to maintain tissue stability (Sikiric et al.).
BPC-157 interacts with growth factor pathways, including VEGF and nitric oxide signaling, to protect against oxidative and inflammatory stress. It is commonly used in research examining vascular regeneration, neuroprotection, and gastrointestinal repair (Józwiak et al.).
The strength of KLOW lies in the biological complementarity of its components. Each peptide targets a different but interconnected pathway in the repair process:
Together, these actions produce multi-level biological synergy, combining anti-inflammatory, regenerative, and vascular-supporting effects.
KLOW provides researchers with a model for studying systemic tissue recovery, inflammation resolution, and cellular communication within complex biological systems.
The KLOW peptide blend offers researchers a versatile tool for modeling multi‐pathway biological processes, particularly those that integrate tissue repair, immune regulation, and vascular function. Because its components act through complementary mechanisms, KLOW enables the study of systemic regeneration rather than isolated molecular effects.
KLOW’s combined activity supports studies on epithelial and muscular repair, extracellular matrix remodeling, and collagen synthesis. The presence of GHK‑Cu, TB‑500, and BPC‑157 creates a synergistic framework for observing coordinated regeneration—from fibroblast activation and cell migration to angiogenesis and oxidative balance. For example, GHK‑Cu has been shown in human cell/tissue studies to up‑regulate genes related to collagen, glycosaminoglycans and antioxidant defense (Pickart et al.; Pickart et al.)
Through the anti‑inflammatory activity of KPV and the immunomodulatory balance it provides, KLOW serves as a model for exploring how cytokine regulation affects tissue healing. It allows researchers to investigate pathways involved in immune tolerance, inflammation resolution, and stress‑induced immune dysregulation, offering insight into maintaining physiological equilibrium during recovery processes (Dalmasso et al.)
The blend’s inclusion of GHK‑Cu, TB‑500 and BPC‑157 promotes microvascular growth and endothelial protection, key processes in oxygen and nutrient delivery during tissue repair. For instance, human cell studies of TB‑500 (or its analogue Thymosin β4) show enhanced endothelial viability and angiogenic potency (Su et al.)
By uniting regenerative, immune and vascular peptides in one formula, KLOW represents a model for studying multi‑system coordination—an essential aspect of complex biological recovery. It enables exploration of how inflammation, repair and circulation interact dynamically across different tissue environments.
Accurate peptide research depends on verified purity, molecular integrity, and compositional precision—factors that are especially critical in multi-peptide formulations such as KLOW. Each component peptide, from GHK-Cu and KPV to TB-500 and BPC-157, must be synthesized and combined under controlled conditions to preserve biological stability and experimental reliability. Even slight variations in concentration or sequence can alter the overall activity profile, making rigorous quality control essential.
Polaris Peptides produces the KLOW peptide blend to exact research-grade specifications, with every constituent verified through third-party purity testing, stability assessment, and sequence validation. This ensures consistency and reproducibility across studies investigating tissue repair, inflammation modulation, and angiogenesis.
In addition to the full KLOW blend, Polaris also offers GHK-Cu, TB-500, and BPC-157 as individual research-grade formulations. This allows researchers to examine each compound’s independent and synergistic effects, supporting both targeted peptide studies and multi-pathway research models.
Researchers studying KLOW peptide synergy, multi-pathway regeneration, or the individual peptides within the blend can rely on Polaris for verified, high-purity materials designed for advanced laboratory applications.
The KLOW Peptide blend represents a new generation of multi-pathway peptide research, uniting the regenerative strength of GHK-Cu, the immune-modulating power of KPV, the structural mobility of TB-500, and the vascular protection of BPC-157.
By engaging multiple biological systems simultaneously, KLOW allows researchers to explore how peptides interact to promote healing, inflammation balance, and cellular communication.
As the field of peptide science continues to expand, KLOW exemplifies how synergistic peptide design can model complex biological repair mechanisms and advance understanding of systemic tissue recovery.
Discount Applied Successfully!
Your savings have been added to the cart.
Join our Polaris Insiders program to get rewarded for loyalty with exclusive deals, news about upcoming products, and more.
You must be 21 years old or older in order to access our website. Please verify your age.
Our products are crafted for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease.